Golden
Immunotherapy

Immunotherapy

Immunotherapy aims to treat disease through activation or suppression of an immune response. For example activating immunotherapies can target cancer and suppressive immunotherapies can target autoimmunity.

All edits

Edits on 1 May 2019
Tao Le
Tao Le edited on 1 May 2019 6:55 pm
Edits made to:
Article (+1 videos) (+116 characters)

Article

PD-1 inhibitors include pembrolizumab and nivolumab.

PD-L1 inhibitors include atezolizumab, avelumab, and durvalumab.



Edits on 29 Mar 2019
Dawson Sewell
Dawson Sewell edited on 29 Mar 2019 7:19 pm
Edits made to:
Infobox (+1 properties)

Infobox

Edits on 20 Mar 2019
Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 20 Mar 2019 12:53 am
Edits made to:
Article (+9/-9 characters)

Article

Poseida Therapeutics - P-PSMA-101, a PSMA-specific stem cellstem cell memory CAR-T drug candidate for prostate cancer

Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 19 Mar 2019 10:46 pm
Edits made to:
Article (+20/-20 characters)

Article

Tumors are thought to perpetuate their survival by reprogramming the metabolism of the host. Since increased metabolic stress can decrease antitumor T-cell immune response some cancer immunotherapycancer immunotherapy strategies aim to normalize metabolic stress.

Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 19 Mar 2019 10:45 pm
Edits made to:
Article (+7/-7 characters)

Article

bluebird bio - Partnered with CelgeneCelgene, developing a CAR-T therapy called bb2121 targeting b-cell maturation antigen (BCMA) for multiple myeloma

Carla Faraguna
Carla Faraguna approved a suggestion from Golden's AI on 19 Mar 2019 9:36 pm
Edits made to:
Article (+15/-15 characters)

Article

Poseida Therapeutics - P-PSMA-101, a PSMA-specific stem cell memory CAR-T drug candidate for prostate cancerprostate cancer

Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 19 Mar 2019 6:16 pm
Edits made to:
Article (+12/-12 characters)

Article

Malignant tumors can be detected by natural killer (NK) cells and T-cells of the immune system because they display tumor-specific antigens, also called neoantigens, which result from mutations in the tumor genome, and are recognized as non-self. Tumor-associated antigens (TAAs) are proteins more abundant on the surface of cancer cellscancer cells compared to normal cells and can initiate a T-cell anti-cancer response. TAAs are shared by a subgroup of patients but neoantigens are unique to individual patient tumors. Tumors acquire certain characteristics that help them evade immune detection and the tumor micro-environment creates an immunosuppressive network. 

Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 19 Mar 2019 6:16 pm
Edits made to:
Article (+11/-11 characters)

Article

Amgen - Using engineered autologous cell therapy (eACTTM) platform from Kite PharmaKite Pharma

Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 19 Mar 2019 6:11 pm
Edits made to:
Article (+17/-17 characters)

Article

CARsgen Therapeutics - anti-Claudin18.2-CAR-T for gastric and pancreatic cancerpancreatic cancer began a Phase I clinical trial in 2017

Meredith Hanel
Meredith Hanel edited on 19 Mar 2019 3:56 pm
Edits made to:
Article (+243/-243 characters)

Article



Tumors are thought to perpetuate their survival by reprogramming the metabolism of the host. Since increased metabolic stress can decrease antitumor T-cell immune response some cancer immunotherapy strategies aim to normalize metabolic stress.

...

Tumors are thought to perpetuate their survival by reprogramming the metabolism of the host. Since increased metabolic stress can decrease antitumor T-cell immune response some cancer immunotherapy strategies aim to normalize metabolic stress.



Meredith Hanel
Meredith Hanel edited on 19 Mar 2019 3:54 pm
Edits made to:
Article (+311 characters)

Article



Immune checkpoint proteins are involved in controlling immune responses. Cancers can activate immune checkpoint mechanisms resulting in suppression of the immune system’s anti-tumor response. Immune checkpoint inhibitors are a type of immunotherapy which utilises antibodies to block immune checkpoint proteins.

Meredith Hanel
Meredith Hanel edited on 19 Mar 2019 3:32 pm
Edits made to:
Article (+1065/-23 characters)

Article

Immunotherapy Companies

Cancer immunotherapy

Malignant tumors can be detected by natural killer (NK) cells and T-cells of the immune system because they display tumor-specific antigens, also called neoantigens, which result from mutations in the tumor genome, and are recognized as non-self. Tumor-associated antigens (TAAs) are proteins more abundant on the surface of cancer cells compared to normal cells and can initiate a T-cell anti-cancer response. TAAs are shared by a subgroup of patients but neoantigens are unique to individual patient tumors. Tumors acquire certain characteristics that help them evade immune detection and the tumor micro-environment creates an immunosuppressive network. 



To enhance the ability of T-cells and NK cells to kill cancer cells, immune cells are generated with modified T-cell receptors (TCRs) or expressing chimeric antigen receptors (CARs) designed to target various tumor antigens and neoantigens. Either the patient's own cells (autogeneic) or allogeneic cells are used to generate these types of immunotherapies.

Cancer immunotherapy companies

Edits on 19 Mar 2019
Meredith Hanel
Meredith Hanel edited on 19 Mar 2019 2:34 am
Edits made to:
Article (+10 characters)
Categories (+1 topics)
Meredith Hanel
Meredith Hanel edited on 19 Mar 2019 2:30 am
Edits made to:
Categories (+2 topics)
Meredith Hanel
Meredith Hanel edited on 19 Mar 2019 2:28 am
Edits made to:
Article (+2358/-17 characters)

Article

CAR-T based

CAR-T cells and TCR engineered cells for cancer treatment

...

Calibr

Calibr - modular ‘switchable’ CAR-T cell that uses antibody-based switch molecules, working towards universal CAR-T based treatments for hematological and solid cancers 

...



Atara Biotherapeutics- Off-the-shelf, allogeneic T-cell immunotherapy

Bellicum Pharmaceuticals - GoCAR-T cells incorporates an activation switch needing both the target cancer cells and rimiducid

bluebird bio - Partnered with Celgene, developing a CAR-T therapy called bb2121 targeting b-cell maturation antigen (BCMA) for multiple myeloma

Carina Biotech

CARsgen Therapeutics - anti-Claudin18.2-CAR-T for gastric and pancreatic cancer began a Phase I clinical trial in 2017

Celgene 

Cellectis - creating “off-the-shelf” allogeneic products called universal chimeric antigen receptor T-cells (UCART)

Cell Design Labs - Throttle™, CAR-T cells with small molecule control of an “on/off” switch and synNotch™, a synthetic gene expression system in CAR-T cells for better tumor recognition and specificity

Celularity - CAR constructs for allogeneic CAR-T/NK products

Celyad - CAR-T NK cell-based immunotherapies for cancer 

Fate Therapeutics - off-the-shelf CAR T-cell product candidate FT819 derived from iPS Cells

Janssen Biotech - Experimental CART-cell therapy LCAR-B38M for myeloma

JW Therapeutics

Kite Pharma - CAR-T cell therapy called Yescarta U.S. FDA approved for treatment of relapsed or refractory large B-cell lymphoma

Medisix Therapeutics

Mustang Bio - proprietary CAR-T technology and developing CAR-T therapies with CRISPR/Cas9 for hematologic malignancies and solid tumors

Nanjing Legend Biotech

Novartis - U.S. FDA approved CAR-T cell therapy, Kymriah, which uses self-derived cells for treatment of B-cell acute lymphoblastic leukemia

Pfizer - Phase I clinical trials ongoing as of 2018 for allogeneic CAR-T cell therapy UCART19

Precision BioSciences - Collaborating with Baxalta to develop allogeneic CAR-T therapies

Poseida Therapeutics - P-PSMA-101, a PSMA-specific stem cell memory CAR-T drug candidate for prostate cancer

Shire

Sorrento Therapeutics - anti-CEA CAR-T in clinical trials with patients with carcinoembryonic antigen–positive (CEA+) cancers

Ziopharm - non-viral “Sleeping Beauty” (SB) platform for manufacturing of genetically modified CAR+ T cells

Meredith Hanel
Meredith Hanel edited on 18 Mar 2019 4:55 pm
Edits made to:
Article (+313/-69 characters)

Article

AbbvieAbbvie - Using Calibr's switchable CAR-T platform against solid tumors and other cancers

...

Allogene TherapeuticsAllogene Therapeutics - Using UCART19 against CD19-expressing hematological malignancies, acute lymphoblastic leukemia

Amgen Amgen - Using engineered autologous cell therapy (eACTTM) platform from Kite Pharma

...

Metabolic immuno-Oncologyimmuno-oncology

Tumors are thought to perpetuate their survival by reprogramming the metabolism of the host. Since increased metabolic stress can decrease antitumor T-cell immune response some cancer immunotherapy strategies aim to normalize metabolic stress.



Agios Agios PharmaceuticalPharmaceuticals - Partnered with Celgene for a metabolic immune-oncology approach that involves altering the metabolic state of immune cells to enhance the immune response to cancer



Meredith Hanel
Meredith Hanel edited on 18 Mar 2019 4:43 pm
Edits made to:
Article (+569 characters)
Further reading (+1 rows) (+3 cells) (+152 characters)
Related Topics (+2 topics)

Article

Immunotherapy Companies

CAR-T based

Abbvie - Using Calibr's switchable CAR-T platform against solid tumors and other cancers

Calibr

Allogene Therapeutics - Using UCART19 against CD19-expressing hematological malignancies, acute lymphoblastic leukemia

Amgen - Using engineered autologous cell therapy (eACT™) platform from Kite Pharma



Metabolic immuno-Oncology

Agios Pharmaceutical - Partnered with Celgene for a metabolic immune-oncology approach that involves altering the metabolic state of immune cells to enhance the immune response to cancer



Immune checkpoint inhibitors



Further reading

Title
Author
Link
Type

CAR-T Companies: The Meteoric Rise Of Cellular Immunotherapies



Web

Related Topics

Meredith Hanel
Meredith Hanel edited on 18 Mar 2019 4:07 pm
Edits made to:
Description (+30/-10 characters)
Topic thumbnail

Immunotherapy

Immunotherapy aims to treat disease through activation or suppression of an immune response. ActivatingFor example activating immunotherapies can target cancer and suppressive immunotherapies can target autoimmunity.

Edits on 25 Feb 2019
Meredith Hanel"Image Thumbnail: Scanning electron micrograph of a human T lymphocyte (also called a T cell) from the immune system of a healthy donor. Credit: NIAID (NIH)"
Meredith Hanel edited on 25 Feb 2019 7:22 pm
Edits made to:
Topic thumbnail

Immunotherapy

Immunotherapy aims to treat disease through activation or suppression of an immune response. For example activating immunotherapies can target cancer and suppressive immunotherapies can target autoimmunity.

Meredith Hanel
Meredith Hanel edited on 25 Feb 2019 6:26 pm
Edits made to:
Description (+186 characters)
Further reading (+1 rows) (+3 cells) (+106 characters)
Related Topics (+1 topics)
Topic thumbnail

Immunotherapy

Immunotherapy aims to treat disease through activation or suppression of an immune response. Activating immunotherapies target cancer and suppressive immunotherapies target autoimmunity.

Further reading

Title
Author
Link
Type

The Future of Immunotherapy: A 20-Year Perspective



Web

Related Topics